Herein, we investigated the capacity of mLOAd703, expressing murine transgenes, to facilitate checkpoint inhibition therapy (anti-PD-1, anti-PD-L1, and anti-TIM-3) in the murine B16 melanoma model, in which resistance to checkpoint inhibitor monotherapy has frequently been demonstrated.11, 12, 13, 14, 15, 16 As mLOAd703 infection is mediated by human CD46, B16 cells previously modified by Fleischli et al. The gene discussed is CD46; the disease is melanoma.